In the latest close session, Adma Biologics (ADMA) was up +1.72% at $18.34. This change outpaced the S&P 500's 0.62% gain on the day. At the same time, the Dow added 0.99%, and the tech-heavy Nasdaq gained 0.65%.
The infectious disease drug developer's shares have seen a decrease of 7.01% over the last month, not keeping up with the Medical sector's loss of 1.22% and the S&P 500's gain of 0.59%.
Investors will be eagerly watching for the performance of Adma Biologics in its upcoming earnings disclosure.
ADMA's full-year Zacks Consensus Estimates are calling for earnings of $0.57 per share and revenue of $0 million. These results would represent year-over-year changes of +16.33% and 0%, respectively.
Investors should also note any recent changes to analyst estimates for Adma Biologics. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, there's been a 8.89% fall in the Zacks Consensus EPS estimate. At present, Adma Biologics boasts a Zacks Rank of #3 (Hold).
In the context of valuation, Adma Biologics is at present trading with a Forward P/E ratio of 21.99. This expresses a premium compared to the average Forward P/E of 20.46 of its industry.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 105, which puts it in the top 43% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ADMA Biologics Inc (ADMA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
